A phase I/II clinical trial, investigating tebentafusp (a bispecific fusion protein targeting gp100) in metastatic melanoma patients reported an increase in serum CXCL10 and reduction in circulating CXCR3+ CD8+ T cells. Here, CXCL10 is linked to metastatic melanoma.